跳到正文
原文
Medical Xpress·· 21 天前精选AI 评分65

dasatinib 治疗复发难治 TFHL 的 II 期试验:TCR 信号相关突变与 CD8 效应 T 细胞扩增或提示应答人群

Tumor mutations and immune activity may reveal who benefits from investigational lymphoma drug

AI 导读

日本筑波大学开展的医生主导、多中心单臂 II 期试验中,原用于治疗白血病的 dasatinib 在复发或难治性 T 滤泡辅助细胞淋巴瘤(TFHL)患者中观察到临床应答,应答者多携带 TCR 信号通路相关突变。

推荐理由

单臂 II 期试验同步分析肿瘤基因与免疫微环境,为复发难治 TFHL 的患者筛选提供生物标志物线索。

正文 · 原文
Predictive biomarkers for dasatinib therapy identified in relapsed or refractory T-follicular helper cell lymphoma
Study design and patient characteristics. Credit: Nature Communications (2026). DOI: 10.1038/s41467-026-78100-z

Researchers at the University of Tsukuba conducted a physician-initiated phase 2 clinical trial of dasatinib in patients with relapsed or refractory T-follicular helper cell lymphoma (TFHL), an aggressive and difficult-to-treat blood cancer. The study identified genetic alterations and features of the immune microenvironment associated with treatment response. These findings may help identify patients who are more likely to benefit from dasatinib and inform the development of personalized treatment strategies and novel immunotherapeutic approaches. The work is published in the journal Nature Communications.

TFHL is a subtype of peripheral T-cell lymphoma associated with a poor prognosis and limited treatment options following relapse. TFHL is characterized by specific molecular abnormalities, including frequent activation of the T-cell receptor (TCR) signaling pathway. In previous phase 1 studies, researchers demonstrated that dasatinib, a drug originally developed to treat leukemia, suppresses abnormal TCR signaling and has shown promising clinical activity in patients with TFHL.

In this study, researchers conducted a physician-initiated, multicenter phase 2 clinical trial involving 13 institutions across Japan to evaluate the efficacy and safety of dasatinib and identify factors associated with treatment response. The research team performed comprehensive genetic analyses of tumor tissue and blood samples, as well as single-cell transcriptomic profiling in 17 patients.

Clinical responses were observed in patients with mutations related to TCR signaling. These patients also exhibited clonal expansion of CD8-positive effector T cells, which play a key role in tumor cell elimination, along with enhanced antitumor immune activity. In contrast, patients with a high burden of clonal hematopoiesis–associated mutations were less likely to benefit from treatment and showed impaired antitumor immune responses. Clonal hematopoiesis is an age-related phenomenon characterized by the acquisition of somatic mutations and subsequent clonal expansion of hematopoietic stem cells.

These findings suggest that both the genetic characteristics of tumors and the immune microenvironment influence the therapeutic efficacy of dasatinib. The identified biomarkers may help guide patient selection, inform treatment strategies in future studies and support the development of therapies targeting the tumor immune microenvironment. In addition, the results provide new insights into the potential role of clonal hematopoiesis in shaping antitumor immunity.

Publication details

Sakurako Suma et al., A multi-center, single-arm, phase 2 trial of dasatinib in T follicular helper cell lymphomas, Nature Communications (2026). DOI: 10.1038/s41467-026-78100-z

Journal information: Nature Communications

Key medical concepts

Dasatinib

Clinical categories

Oncology

Who's behind this story?

Gaby Clark

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Tumor mutations and immune activity may reveal who benefits from investigational lymphoma drug (2026, October 29) retrieved 29 October 2026 from https://medicalxpress.com/news/2026-10-tumor-mutations-immune-reveal-benefits.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com